KLP Kapitalforvaltning AS Acquires 300 Shares of United Therapeutics Corporation $UTHR

KLP Kapitalforvaltning AS raised its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 0.5% during the second quarter, HoldingsChannel reports. The fund owned 59,900 shares of the biotechnology company’s stock after purchasing an additional 300 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in United Therapeutics were worth $17,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Chung Wu Investment Group LLC bought a new stake in United Therapeutics during the 2nd quarter valued at $29,000. QRG Capital Management Inc. raised its holdings in United Therapeutics by 6.2% during the 2nd quarter. QRG Capital Management Inc. now owns 17,770 shares of the biotechnology company’s stock valued at $5,106,000 after acquiring an additional 1,045 shares during the period. Ascent Group LLC raised its holdings in United Therapeutics by 21.7% during the 2nd quarter. Ascent Group LLC now owns 874 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 156 shares during the period. Hilltop National Bank bought a new stake in United Therapeutics during the 2nd quarter valued at $341,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in United Therapeutics by 9.2% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,016 shares of the biotechnology company’s stock valued at $1,154,000 after acquiring an additional 338 shares during the period. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $448.93 on Thursday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The firm has a fifty day moving average of $365.94 and a 200 day moving average of $321.87. The firm has a market capitalization of $20.25 billion, a PE ratio of 17.52, a price-to-earnings-growth ratio of 6.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. During the same quarter last year, the firm posted $5.85 earnings per share. The firm’s revenue was up 11.7% on a year-over-year basis. On average, sell-side analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of United Therapeutics in a report on Friday, September 26th. They set an “outperform” rating and a $569.00 target price on the stock. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a research report on Friday, September 5th. JPMorgan Chase & Co. reduced their price target on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating for the company in a research report on Tuesday, July 8th. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a research report on Wednesday, September 3rd. Finally, UBS Group boosted their price target on shares of United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research report on Monday, September 29th. Ten investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $449.57.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $11,356,133.75. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the company’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total transaction of $9,396,900.00. The disclosure for this sale can be found here. Insiders sold 257,935 shares of company stock valued at $103,782,672 over the last quarter. 10.30% of the stock is owned by company insiders.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.